Daicel stock rating cut by Morgan Stanley on profit outlook concerns

Morgan Stanley downgraded Daicel Corporation from Overweight to Equalweight, lowering the price target to JPY1,400 from JPY2,300 due to concerns about inventory valuation impacts negatively affecting fiscal 2026 profits by JPY9.2 billion after boosting fiscal 2025 by JPY9.9 billion. The downgrade reflects challenges including difficulties in assessing true profitability, high foreign exchange sensitivity, and stagnant top-line growth, with Morgan Stanley noting the stock may remain a "value trap" despite expecting high return on equity.

Analysis

Morgan Stanley has downgraded Daicel Corporation (4202:JP) to Equalweight from Overweight, concurrently reducing its price target substantially to JPY1,400 from JPY2,300. This revision is primarily driven by a reassessment of Daicel's fiscal 2026 operating profit outlook, which is anticipated to be negatively impacted by JPY9.2 billion due to inventory valuation effects, a stark reversal from the JPY9.9 billion positive contribution in fiscal 2025. The investment bank also flagged several headwinds, including challenges in discerning Daicel's underlying profitability, a high sensitivity to foreign exchange fluctuations where a one-yen appreciation against the U.S. dollar erodes 12-month operating profit by JPY800 million, and persistent stagnant top-line growth. The new price target reflects a significantly more conservative valuation, based on a forward price-to-earnings ratio of 7.2 times fiscal 2027 estimates, a departure from the previous 11.0 times multiple derived from fine chemicals stock averages, now employing the 10-year average forward P/E minus one standard deviation. Despite Morgan Stanley's continued expectation of high return on equity, the firm cautions that Daicel's stock may remain a "value trap" for an extended period.

Key Decisions for Investors

• Investors should reassess their positions in Daicel Corporation given the significant downgrade, substantial price target reduction, and Morgan Stanley's concerns regarding near-term profitability headwinds from inventory valuation and stagnant growth.
• Particular attention should be paid to the company's upcoming earnings releases for clarity on inventory effects, actual underlying profitability, and any strategies to mitigate high foreign exchange sensitivity and reignite top-line growth.
• The "value trap" warning and the shift to a lower valuation multiple suggest a cautious approach, even for investors attracted by the potential for high return on equity, until greater visibility on sustainable earnings is achieved.